PMID- 27855622
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20231213
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 24
IP  - 1
DP  - 2017
TI  - The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non 
      Small Cell Lung Cancer.
PG  - 3-13
LID - 10.2174/0929867324666161118125103 [doi]
AB  - Angiogenesis is one of the most important phenomena sustaining tumor development 
      and metastatization, including for non small cell lung cancer (NSCLC). A dominant 
      role in angiogenesis is played by the vascular endothelial growth factor (VEGF) 
      and its signaling pathway. Ramucirumab, is a fully human immunoglobulin G1 
      monoclonal antibody that binds to the extracellular domain of the VEGF receptor-2 
      (VEGFR-2) with high specificity and affinity blocking the interaction of VEGFR-2 
      and VEGF ligands, thus inhibiting their signaling pathways and the consequential 
      endothelial proliferation and migration. A recent phase III randomized trial 
      named REVEL, demonstrated the efficacy of ramucirumab in combination with 
      docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA 
      approval in this clinical setting. In the REVEL trial advanced NSCLC patients 
      whose disease had progressed after first line platinum-based chemotherapy, were 
      administered ramucirumab plus docetaxel or placebo plus docetaxel. More than 
      1,250 patients were treated and patients randomized to the treatment with 
      ramucirumab plus docetaxel showed a significant longer median overall survival 
      compared to those randomized to chemotherapy only. Ramucirumab is the first 
      antiangiogenetic agent approved in the treatment both of squamous and non 
      squamous NSCLC. In fact, it is not associated with increased risk of respiratory 
      bleeding in the squamous histology, and also has demonstrated efficacy in both 
      histology types. The role of ramucirumab, already cleared in the second-line 
      treatment of advanced NSCLC, needs to be clarified further and is currently being 
      explored also in the first-line treatment of advanced NSCLC.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Maione, Paolo
AU  - Maione P
FAU - Sgambato, Assunta
AU  - Sgambato A
FAU - Casaluce, Francesca
AU  - Casaluce F
FAU - Sacco, Paola Claudia
AU  - Sacco PC
FAU - Santabarbara, Giuseppe
AU  - Santabarbara G
FAU - Rossi, Antonio
AU  - Rossi A
FAU - Gridelli, Cesare
AU  - Gridelli C
AD  - Division of Medical Oncology , "S. G. Moscati" Hospital, Avellino, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Angiogenesis Inhibitors/chemistry/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal/chemistry/*pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/chemistry/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Neovascularization, Pathologic/*drug therapy/pathology
MH  - Ramucirumab
OTO - NOTNLM
OT  - Angiogenesis
OT  - VEGF
OT  - VEGFR2
OT  - advanced NSCLC
OT  - ramucirumab
OT  - second-line treatment
EDAT- 2016/11/20 06:00
MHDA- 2017/04/05 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/03/14 00:00 [received]
PHST- 2016/09/30 00:00 [revised]
PHST- 2016/11/16 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - CMC-EPUB-79803 [pii]
AID - 10.2174/0929867324666161118125103 [doi]
PST - ppublish
SO  - Curr Med Chem. 2017;24(1):3-13. doi: 10.2174/0929867324666161118125103.